Pharmakogenetik Medicheck: what does this mean exactly?

The Pharmakogenetik Medicheck is a DNA test that analyzes genetic variants in drug-metabolizing enzymes (e.g., CYP2D6, CYP2C19, CYP2C9, VKORC1). It aims to indicate how quickly or slowly a person processes certain medications – classifying them as 'poor', 'intermediate', 'normal', or 'ultra-rapid metabolizers'. The evidence for many of these markers is human-moderate to strong (clinical studies, guidelines like CPIC). However, a genetic test does not replace medical advice. Effect sizes are often moderate, and dose adjustments must always be made in a clinical context. The test can serve as orientation but not as a sole decision basis. Moreover, not all relevant genes are covered – the selection is commercially driven. Beware of overblown promises: 'personalized medicine' is a process, not a one-time result. Users should discuss results with a physician or pharmacist knowledgeable in pharmacogenetics.